{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T08:31:09Z","timestamp":1791621069118,"version":"4.3.4"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,2,9]],"date-time":"2010-02-09T00:00:00Z","timestamp":1265673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2010,2,9]],"date-time":"2010-02-09T00:00:00Z","timestamp":1265673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1038\/nrrheum.2009.279","type":"journal-article","created":{"date-parts":[[2010,2,9]],"date-time":"2010-02-09T00:13:15Z","timestamp":1265674395000},"page":"165-174","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":178,"title":["Tumor necrosis factor blockade and the risk of viral infection"],"prefix":"10.1038","volume":"6","author":[{"given":"Seo Young","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,2,9]]},"reference":[{"key":"BFnrrheum2009279_CR1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1136\/ard.58.2008.i32","volume":"58","author":"G Kollias","year":"1999","unstructured":"Kollias, G., Douni, E., Kassiotis, G. & Kontoyiannis, D. The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Ann. Rheum. Dis. 58, 132\u2013139 (1999).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2009279_CR2","doi-asserted-by":"crossref","unstructured":"Furst, D. The risk of infections with biologic therapies for rheumatoid arthritis. Semin. Arthritis Rheum. [doi:10.1016\/j.semarthrit.2008.10.002].","DOI":"10.1016\/j.semarthrit.2008.10.002"},{"key":"BFnrrheum2009279_CR3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s11926-008-0062-1","volume":"10","author":"M Crawford","year":"2008","unstructured":"Crawford, M. & Curtis, J. Tumor necrosis factor inhibitors and infection complications. Curr. Rheumatol. Rep. 10, 383\u2013389 (2008).","journal-title":"Curr. Rheumatol. Rep."},{"key":"BFnrrheum2009279_CR4","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1002\/art.21978","volume":"54","author":"W Dixon","year":"2006","unstructured":"Dixon, W.  et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 54, 2368\u20132376 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009279_CR5","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/art.21568","volume":"54","author":"F Wolfe","year":"2006","unstructured":"Wolfe, F., Caplan, L. & Michaud, K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 54, 628\u2013634 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009279_CR6","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1002\/art.22600","volume":"56","author":"S Schneeweiss","year":"2007","unstructured":"Schneeweiss, S.  et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 56, 1754\u20131764 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009279_CR7","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz, T.  et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275\u20132285 (2006).","journal-title":"JAMA"},{"key":"BFnrrheum2009279_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1146\/annurev.immunol.19.1.65","volume":"19","author":"L Guidotti","year":"2001","unstructured":"Guidotti, L. & Chisari, F. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 19 65\u201391 (2001).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnrrheum2009279_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.it.2007.10.008","volume":"29","author":"G Herbein","year":"2008","unstructured":"Herbein, G. & Khan, K. Is HIV infection a TNF receptor signalling-driven disease? Trends Immunol. 29, 61\u201367 (2008).","journal-title":"Trends Immunol."},{"key":"BFnrrheum2009279_CR10","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.semarthrit.2007.10.011","volume":"38","author":"M Carroll","year":"2008","unstructured":"Carroll, M. & Bond, M. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin. Arthritis Rheum. 38, 208\u2013217 (2008).","journal-title":"Semin. Arthritis Rheum."},{"key":"BFnrrheum2009279_CR11","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1111\/j.1365-2133.2008.08851.x","volume":"159","author":"S Domm","year":"2008","unstructured":"Domm, S., Cinatl, J. & Mrowietz, U. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br. J. Dermatol. 159, 1217\u20131228 (2008).","journal-title":"Br. J. Dermatol."},{"key":"BFnrrheum2009279_CR12","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1056\/NEJM199606273342607","volume":"334","author":"F Bazzoni","year":"1996","unstructured":"Bazzoni, F. & Beutler, B. The tumor necrosis factor ligand and receptor families. N. Engl. J. Med. 334, 1717\u20131725 (1996).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2009279_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1086\/314572","volume":"179","author":"P Aukrust","year":"1999","unstructured":"Aukrust, P.  et al. Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: persistent TNF activation is associated with virologic and immunologic treatment failure. J. Infect. Dis. 179, 74\u201382 (1999).","journal-title":"J. Infect. Dis."},{"key":"BFnrrheum2009279_CR14","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1182\/blood.V99.5.1666","volume":"99","author":"L de Oliveira Pinto","year":"2002","unstructured":"de Oliveira Pinto, L., Garcia, S., Lecoeur, H., Rapp, C. & Gougeon, M. Increased sensitivity of T lymphocytes to tumor necrosis factor receptor 1 (TNFR1)- and TNFR2-mediated apoptosis in HIV infection: relation to expression of Bcl-2 and active caspase-8 and caspase-3. Blood 99, 1666\u20131675 (2002).","journal-title":"Blood"},{"key":"BFnrrheum2009279_CR15","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/35037728","volume":"407","author":"P Krammer","year":"2000","unstructured":"Krammer, P. CD95's deadly mission in the immune system. Nature 407, 789\u2013795 (2000).","journal-title":"Nature"},{"key":"BFnrrheum2009279_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1084\/jem.185.1.55","volume":"185","author":"A Badley","year":"1997","unstructured":"Badley, A.  et al. Macrophage-dependent apoptosis of CD4+ T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor. Exp. Med. 185, 55\u201364 (1997).","journal-title":"Exp. Med."},{"key":"BFnrrheum2009279_CR17","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nri1184","volume":"3","author":"B Aggarwal","year":"2003","unstructured":"Aggarwal, B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3, 745\u2013756 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"BFnrrheum2009279_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1469-0691.1998.tb00327.x","volume":"4","author":"J Bedini","year":"1998","unstructured":"Bedini, J.  et al. Serum levels of beta2-microglobulin, neopterin, TNF-alpha and soluble receptors of TNF-alpha and interleukin-2 in intravenous drug abusers according to HIV-1 status and stage of the HIV-1 infection. Clin. Microbiol. Infect. 4, 4\u201310 (1998).","journal-title":"Clin. Microbiol. Infect."},{"key":"BFnrrheum2009279_CR19","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1084\/jem.173.3.589","volume":"173","author":"G Poli","year":"1991","unstructured":"Poli, G.  et al. Transforming growth factor beta suppresses human immunodeficiency virus expression and replication in infected cells of the monocyte\/macrophage lineage. Exp. Med. 173, 589\u2013597 (1991).","journal-title":"Exp. Med."},{"key":"BFnrrheum2009279_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/infdis\/174.1.63","volume":"174","author":"R Walker","year":"1996","unstructured":"Walker, R.  et al. Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1. J. Infect. Dis. 174, 63\u201368 (1996).","journal-title":"J. Infect. Dis."},{"key":"BFnrrheum2009279_CR21","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.4065\/75.10.1093","volume":"75","author":"D Aboulafia","year":"2000","unstructured":"Aboulafia, D., Bundow, D., Wilske, K. & Ochs, U. Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin. Proc. 75, 1093\u20131098 (2000).","journal-title":"Mayo Clin. Proc."},{"key":"BFnrrheum2009279_CR22","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/j.0007-0963.2004.05885.x","volume":"150","author":"U Bartke","year":"2004","unstructured":"Bartke, U.  et al. Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab. Br. J. Dermatol. 150, 784\u2013786 (2004).","journal-title":"Br. J. Dermatol."},{"key":"BFnrrheum2009279_CR23","first-page":"407","volume":"30","author":"N Gaylis","year":"2003","unstructured":"Gaylis, N. Infliximab in the treatment of an HIV positive patient with Reiter's syndrome. J. Rheumatol. 30, 407\u2013411 (2003).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2009279_CR24","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1136\/gut.2006.101386","volume":"55","author":"B Beltran","year":"2006","unstructured":"Beltran, B.  et al. Safe and effective application of anti-TNF-alpha in a patient infected with HIV and concomitant Crohn's disease. Gut 55, 1670\u20131671 (2006).","journal-title":"Gut"},{"key":"BFnrrheum2009279_CR25","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1001\/archinte.166.16.1783","volume":"166","author":"J Filippi","year":"2006","unstructured":"Filippi, J.  et al. Infliximab and human immunodeficiency virus infection: Viral load reduction and CD4+ T-cell loss related to apoptosis. Arch. Intern. Med. 166, 1783\u20131784 (2006).","journal-title":"Arch. Intern. Med."},{"key":"BFnrrheum2009279_CR26","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/00002030-200401230-00015","volume":"18","author":"RS Wallis","year":"2004","unstructured":"Wallis, R. S.  et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 18, 257\u2013264 (2004).","journal-title":"AIDS"},{"key":"BFnrrheum2009279_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/01.rhu.0000260411.75599.39","volume":"13","author":"PP Kaur","year":"2007","unstructured":"Kaur, P. P., Chan, V. C. & Berney, S. N. Successful etanercept use in an HIV-positive patient with rheumatoid arthritis. J. Clin. Rheumatol. 13, 79\u201380 (2007).","journal-title":"Clin. Rheumatol."},{"key":"BFnrrheum2009279_CR28","first-page":"1353","volume":"34","author":"GK Linardaki","year":"2007","unstructured":"Linardaki, G. K., Katsarou, O., Ioannidou, P., Karafoulidou, A. & Boki, K. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. J. Rheumatol. 34, 1353\u20131355 (2007).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2009279_CR29","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jbspin.2006.05.012","volume":"74","author":"J Sellam","year":"2007","unstructured":"Sellam, J.  et al. Use of infliximab to treat psoriatic arthritis in HIV-positive patients. Joint Bone Spine 74, 197\u2013200 (2007).","journal-title":"Joint Bone Spine"},{"key":"BFnrrheum2009279_CR30","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/ard.2007.081513","volume":"67","author":"E Cepeda","year":"2008","unstructured":"Cepeda, E., Williams, F., Ishimori, M., Weisman, M. & Reveille, J. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann. Rheum. Dis. 67, 710\u2013712 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2009279_CR31","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1001\/archderm.144.4.453","volume":"144","author":"M Mikhail","year":"2008","unstructured":"Mikhail, M., Weinberg, J. M. & Smith, B. L. Successful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virus. Arch. Dermatol. 144, 453\u2013456 (2008).","journal-title":"Arch. Dermatol."},{"key":"BFnrrheum2009279_CR32","first-page":"604","volume":"5","author":"H Shahbazian","year":"2007","unstructured":"Shahbazian, H. & Ehsanpour, A. An outbreak of chickenpox in adult renal transplant recipients. Exp. Clin. Transplant. 5, 604\u2013606 (2007).","journal-title":"Exp. Clin. Transplant."},{"key":"BFnrrheum2009279_CR33","volume-title":"Epidemiology and natural history of herpes zoster and postherpetic neuralgia","author":"R Dworkin","year":"2001","unstructured":"Dworkin, R. & Schmader, K. Epidemiology and natural history of herpes zoster and postherpetic neuralgia (eds Watson, C. & Gershon, A.) (Elsevier Press, New York, 2001)."},{"key":"BFnrrheum2009279_CR34","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.1086\/522152","volume":"197","author":"K Schmader","year":"2008","unstructured":"Schmader, K., Gnann, J. J. & Watson, C. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J. Infect. Dis. 197, S207\u2013S215 (2008).","journal-title":"J. Infect. Dis."},{"key":"BFnrrheum2009279_CR35","doi-asserted-by":"publisher","first-page":"274","DOI":"10.4065\/84.3.274","volume":"84","author":"P Sampathkumar","year":"2009","unstructured":"Sampathkumar, P., Drage, L. & Martin, D. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin. Proc. 84, 274\u2013280 (2009).","journal-title":"Mayo Clin. Proc."},{"key":"BFnrrheum2009279_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/00128071-200607010-00003","volume":"7","author":"H Tan","year":"2006","unstructured":"Tan, H. & Goh, C. Viral infections affecting the skin in organ transplant recipients: epidemiology and current management strategies. Am. J. Clin. Dermatol. 7, 13\u201329 (2006).","journal-title":"Am. J. Clin. Dermatol."},{"key":"BFnrrheum2009279_CR37","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/art.23112","volume":"57","author":"AL Smitten","year":"2007","unstructured":"Smitten, A. L.  et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum. 57, 1431\u20131438 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009279_CR38","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1097\/01.inf.0000226841.03751.1f","volume":"25","author":"PPW Lee","year":"2006","unstructured":"Lee, P. P. W., Lee, T.-L., Ho, M. H.-K., Wong, W. H. S. & Lau, Y.-L. Herpes zoster in juvenile-onset systemic lupus erythematosus: incidence, clinical characteristics and risk factors. Pediatr. Infect. Dis. J. 25, 728\u2013732 (2006).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"BFnrrheum2009279_CR39","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1046\/j.1365-2230.1999.00490.x","volume":"24","author":"O Ishikawa","year":"1999","unstructured":"Ishikawa, O., Abe, M. & Miyachi, Y. Herpes zoster in Japanese patients with systemic lupus erythematosus. Clin. Exp. Dermatol. 24, 327\u2013328 (1999).","journal-title":"Clin. Exp. Dermatol."},{"key":"BFnrrheum2009279_CR40","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1093\/rheumatology\/kel328","volume":"45","author":"F Wolfe","year":"2006","unstructured":"Wolfe, F., Michaud, K. & Chakravarty, E. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford) 45, 1370\u20131375 (2006).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum2009279_CR41","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/jama.2009.146","volume":"301","author":"A Strangfeld","year":"2009","unstructured":"Strangfeld, A.  et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301, 737\u2013744 (2009).","journal-title":"JAMA"},{"key":"BFnrrheum2009279_CR42","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1136\/ard.61.7.661","volume":"61","author":"D Baumgart","year":"2002","unstructured":"Baumgart, D. & Dignass, A. Shingles following infliximab infusion. Ann. Rheum. Dis. 61, 661 (2002).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2009279_CR43","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1136\/pmj.2003.014373","volume":"80","author":"A Kinder","year":"2004","unstructured":"Kinder, A., Stephens, S., Mortimer, N. & Sheldon, P. Severe herpes zoster after infliximab infusion. Postgrad. Med. J. 80, 26 (2004).","journal-title":"Postgrad. Med. J."},{"key":"BFnrrheum2009279_CR44","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/j.1365-2133.2007.07682.x","volume":"156","author":"HH Lee","year":"2007","unstructured":"Lee, H. H.  et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. British J. Dermatol. 156, 486\u2013491 (2007).","journal-title":"British J. Dermatol."},{"key":"BFnrrheum2009279_CR45","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1111\/j.1572-0241.2004.41389_7.x","volume":"99","author":"VS Leung","year":"2004","unstructured":"Leung, V. S., Nguyen, M. T. & Bush, T. M. Disseminated primary varicella after initiation of infliximab for Crohn's disease. Am. J. Gastroenterol. 99, 2503\u20132504 (2004).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrrheum2009279_CR46","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jaad.2008.10.002","volume":"60","author":"N Balato","year":"2009","unstructured":"Balato, N., Gaudiello, F., Balato, A. & Ayala, F. Development of primary varicella infection during infliximab treatment for psoriasis. J. Am. Acad. Dermatol. 60, 709\u2013710 (2009).","journal-title":"J. Am. Acad. Dermatol."},{"key":"BFnrrheum2009279_CR47","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1159\/000149311","volume":"217","author":"S Becart","year":"2008","unstructured":"Becart, S. & Segaert, S. Recurrent varicella in an adult psoriasis patient treated with etanercept. Dermatology 217, 260\u2013261 (2008).","journal-title":"Dermatology"},{"key":"BFnrrheum2009279_CR48","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/j.1365-4632.2006.02779.x","volume":"45","author":"H-J Choi","year":"2006","unstructured":"Choi, H.-J., Kim, M.-Y., Kim, H. O. & Park, Y. M. An atypical varicella exanthem associated with the use of infliximab. Int. J. Dermatol. 45, 999\u20131000 (2006).","journal-title":"Int. J. Dermatol."},{"key":"BFnrrheum2009279_CR49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000080075","volume":"70","author":"J Seiderer","year":"2004","unstructured":"Seiderer, J., Goke, B. & Ochsenkuhn, T. Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital. Digestion 70, 3\u20139 (2004).","journal-title":"Digestion"},{"key":"BFnrrheum2009279_CR50","first-page":"2517","volume":"31","author":"H Vonkeman","year":"2004","unstructured":"Vonkeman, H., ten Napel, C., Rasker, H. & van de Laar, M. Disseminated primary varicella infection during infliximab treatment. J. Rheumatol. 31, 2517\u20132518 (2004).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2009279_CR51","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jbspin.2007.10.011","volume":"75","author":"D Wendling","year":"2008","unstructured":"Wendling, D., Streit, G., Toussirot, E. & Prati, C. Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease. Joint Bone Spine 75, 540\u2013543 (2008).","journal-title":"Joint Bone Spine"},{"key":"BFnrrheum2009279_CR52","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1159\/000232389","volume":"219","author":"S Tresch","year":"2009","unstructured":"Tresch, S., Tr\u00fceb, R., Kamarachev, J., French, L. & Hofbauer, G. Disseminated herpes zoster mimicking rheumatoid vasculitis in a rheumatoid arthritis patient on etanercept. Dermatology 219, 347\u2013349 (2009).","journal-title":"Dermatology"},{"key":"BFnrrheum2009279_CR53","doi-asserted-by":"crossref","unstructured":"Greenberg, J.  et al. Association of methotrexate and TNF antagonists with risk of infection outcomes including opportunistic infections in the CORRONA registry. Ann. Rheum. Dis. [doi:10.1136\/ard.2008.089276].","DOI":"10.1136\/ard.2008.089276"},{"key":"BFnrrheum2009279_CR54","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1086\/598331","volume":"48","author":"J McDonald","year":"2009","unstructured":"McDonald, J.  et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin. Infect. Dis. 48, 1364\u20131371 (2009).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrrheum2009279_CR55","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1468-3083.2006.01984.x","volume":"21","author":"D Lee","year":"2007","unstructured":"Lee, D., Kim, H., Song, Y. & Cho, K. Development of varicella during adalimumab therapy. J. Eur. Acad. Dermatol. Venereol. 21, 687\u2013688 (2007).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"BFnrrheum2009279_CR56","unstructured":"Centers for Diseases Control and Prevention. Epstein\u2013Barr virus and infectious mononucleosis http:\/\/www.cdc.gov\/ncidod\/diseases\/ebv.htm (2006)."},{"key":"BFnrrheum2009279_CR57","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.berh.2008.09.007","volume":"22","author":"E Toussirot","year":"2008","unstructured":"Toussirot, E. & Roudier, J. Epstein\u2013Barr virus in autoimmune diseases. Best Pract. Res. Clin. Rheumatol. 22, 883\u2013896 (2008).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"BFnrrheum2009279_CR58","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1172\/JCI110127","volume":"67","author":"M Alspaugh","year":"1981","unstructured":"Alspaugh, M., Henle, G., Lennette, E. & Henle, W. Elevated levels of antibodies to Epstein\u2013Barr virus antigens in sera and synovial fluids of patients with rheumatoid arthritis. J. Clin. Invest. 67, 1134\u20131140 (1981).","journal-title":"J. Clin. Invest."},{"key":"BFnrrheum2009279_CR59","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/art.22783","volume":"57","author":"N Balandraud","year":"2007","unstructured":"Balandraud, N.  et al. Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase Epstein\u2013Barr virus load in patients with rheumatoid arthritis. Arthritis Rheum. 57, 762\u2013767 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009279_CR60","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00296-008-0775-5","volume":"29","author":"I Sari","year":"2009","unstructured":"Sari, I.  et al. Atypical infectious mononucleosis in a patient receiving tumor necrosis factor alpha inhibitory treatment. Rheumatol. Int. 29, 825\u2013826 (2009).","journal-title":"Rheumatol. Int."},{"key":"BFnrrheum2009279_CR61","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00296-007-0467-6","volume":"28","author":"S Park","year":"2008","unstructured":"Park, S., Kim, C., Kim, J. & Choe, J. Spontaneous regression of EBV-associated diffuse lymphoproliferative disease in a patient with rheumatoid arthritis after discontinuation of etanercept treatment. Rheumatol. Int. 28, 475\u2013477 (2008).","journal-title":"Rheumatol. Int."},{"key":"BFnrrheum2009279_CR62","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3109\/s10165-008-0053-0","volume":"18","author":"A Komatsuda","year":"2008","unstructured":"Komatsuda, A., Wakui, H., Nimura, T. & Sawada, K. Reversible infliximab-related lymphoproliferative disorder associated with Epstein\u2013Barr virus in a patient with rheumatoid arthritis. Mod. Rheumatol. 18, 315\u2013318 (2008).","journal-title":"Mod. Rheumatol."},{"key":"BFnrrheum2009279_CR63","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/00054725-200407000-00015","volume":"10","author":"A Losco","year":"2004","unstructured":"Losco, A.  et al. Epstein\u2013Barr virus-associated lymphoma in Crohn's disease. Inflamm. Bowel Dis. 10, 425\u2013429 (2004).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrrheum2009279_CR64","volume-title":"Fields's virology","author":"E Mocarski","year":"2001","unstructured":"Mocarski, E. & Courcelle, C. in Fields's virology (eds Knipe, D. & Howley, P.) (Lippincott Williams & Wilkins, Philadelphia, 2001)."},{"key":"BFnrrheum2009279_CR65","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1086\/425123","volume":"39","author":"G Haerter","year":"2004","unstructured":"Haerter, G.  et al. Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis. Clin. Infect. Dis. 39, e88\u2013e94 (2004).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrrheum2009279_CR66","doi-asserted-by":"publisher","first-page":"523","DOI":"10.2340\/00015555-0491","volume":"88","author":"B Petersen","year":"2008","unstructured":"Petersen, B. & Lorentzen, H. Cytomegalovirus complicating biological immunosuppressive therapy in two patients with psoriasis receiving treatment with etanercept or efalizumab. Acta Derm. Venereol. 88, 523\u2013524 (2008).","journal-title":"Acta Derm. Venereol."},{"key":"BFnrrheum2009279_CR67","first-page":"31","volume":"58","author":"I Pontikaki","year":"2006","unstructured":"Pontikaki, I.  et al. Side effects of anti-TNFalpha therapy in juvenile idiopathic arthritis [Italian]. Reumatismo 58, 31\u201338 (2006).","journal-title":"Reumatismo"},{"key":"BFnrrheum2009279_CR68","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.3748\/wjg.14.2912","volume":"14","author":"I Sari","year":"2008","unstructured":"Sari, I.  et al. Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment. World J. Gastroenterol. 14, 2912\u20132914 (2008).","journal-title":"World J. Gastroenterol."},{"key":"BFnrrheum2009279_CR69","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1126\/science.7997879","volume":"266","author":"Y Chang","year":"1994","unstructured":"Chang, Y.  et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266, 1865\u20131869 (1994).","journal-title":"Science"},{"key":"BFnrrheum2009279_CR70","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1093\/oxfordjournals.aje.a009440","volume":"147","author":"P Moore","year":"1998","unstructured":"Moore, P. & Chang, Y. Kaposi's sarcoma (KS), KS-associated herpesvirus, and the criteria for causality in the age of molecular biology. Am. J. Epidemiol. 147, 217\u2013221 (1998).","journal-title":"Am. J. Epidemiol."},{"key":"BFnrrheum2009279_CR71","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJM200004063421407","volume":"342","author":"K Antman","year":"2000","unstructured":"Antman, K. & Chang, Y. Kaposi's sarcoma. N. Engl. J. Med. 342, 1027\u20131038 (2000).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2009279_CR72","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/BF02207213","volume":"11","author":"P Casoli","year":"1992","unstructured":"Casoli, P. & Tumiati, B. Rheumatoid arthritis, corticosteroid therapy and Kaposi's sarcoma: a coincidence? A case and review of literature. Clin. Rheumatol. 11, 432\u2013435 (1992).","journal-title":"Clin. Rheumatol."},{"key":"BFnrrheum2009279_CR73","first-page":"326","volume":"32","author":"W Louthrenoo","year":"2003","unstructured":"Louthrenoo, W., Kasitanon, N., Mahanuphab, P., Bhoopat, L. & Thongprasert, S. Kaposi's sarcoma in rheumatic diseases. Semin. Arthritis Rheum. 32, 326\u2013333 (2003).","journal-title":"Semin. Arthritis Rheum."},{"key":"BFnrrheum2009279_CR74","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5070\/D31C94R8ZM","volume":"12","author":"A Kuttikat","year":"2006","unstructured":"Kuttikat, A., Joshi, A., Saeed, I. & Chakravarty, K. Kaposi sarcoma in a patient with giant cell arteritis. Dermatol. Online J. 12, 16 (2006).","journal-title":"Dermatol. Online J."},{"key":"BFnrrheum2009279_CR75","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S0190-9622(08)80128-4","volume":"24","author":"C Soria","year":"1991","unstructured":"Soria, C.  et al. Kaposi's sarcoma in a patient with temporal arteritis treated with corticosteroid. J. Am. Acad. Dermatol. 24, 1027\u20131028 (1991).","journal-title":"J. Am. Acad. Dermatol."},{"key":"BFnrrheum2009279_CR76","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1136\/ard.62.7.684","volume":"62","author":"CD Cohen","year":"2003","unstructured":"Cohen, C. D., Horster, S., Sander, C. A. & Bogner, J. R. Kaposi's sarcoma associated with tumour necrosis factor alpha neutralising therapy. Ann. Rheum. Dis. 62, 684 (2003).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2009279_CR77","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/ibd.20131","volume":"13","author":"A Lavagna","year":"2007","unstructured":"Lavagna, A.  et al. Infliximab and the risk of latent viruses reactivation in active Crohn's disease. Inflamm. Bowel Dis. 13, 896\u2013902 (2007).","journal-title":"Inflamm. Bowel Dis."},{"key":"BFnrrheum2009279_CR78","first-page":"1","volume":"56","author":"L Markowitz","year":"2007","unstructured":"Markowitz, L.  et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 56, 1\u201324 (2007).","journal-title":"MMWR Recomm. Rep."},{"key":"BFnrrheum2009279_CR79","first-page":"453","volume":"7","author":"A Handisurya","year":"2009","unstructured":"Handisurya, A., Schellenbacher, C. & Kirnbauer, R. Diseases caused by human papillomaviruses (HPV). J. Dtsch. Dermatol. Ges. 7, 453\u2013466 (2009).","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"BFnrrheum2009279_CR80","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1473-3099(09)70108-2","volume":"9","author":"M Einstein","year":"2009","unstructured":"Einstein, M.  et al. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect. Dis. 9, 347\u2013356 (2009).","journal-title":"Lancet Infect. Dis."},{"key":"BFnrrheum2009279_CR81","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/jnci\/dji073","volume":"97","author":"H Strickler","year":"2005","unstructured":"Strickler, H.  et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J. Natl Cancer Inst. 97, 577\u2013586 (2005).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrrheum2009279_CR82","doi-asserted-by":"publisher","first-page":"11070","DOI":"10.1158\/0008-5472.CAN-06-2034","volume":"66","author":"A Garcia-Pineres","year":"2006","unstructured":"Garcia-Pineres, A.  et al. Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women. Cancer Res. 66, 11070\u201311076 (2006).","journal-title":"Cancer Res."},{"key":"BFnrrheum2009279_CR83","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.bbmt.2008.07.005","volume":"14","author":"B Savani","year":"2008","unstructured":"Savani, B.  et al. Increased risk of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation\u2014implications for screening and HPV vaccination. Biol. Blood Marrow Transplant. 14, 1072\u20131075 (2008).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"BFnrrheum2009279_CR84","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.transproceed.2009.03.015","volume":"41","author":"M Veroux","year":"2009","unstructured":"Veroux, M.  et al. Surveillance of human papilloma virus infection and cervical cancer in kidney transplant recipients: preliminary data. Transplant. Proc. 41, 1191\u20131194 (2009).","journal-title":"Transplant. Proc."},{"key":"BFnrrheum2009279_CR85","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.healun.2003.07.018","volume":"23","author":"MA Malouf","year":"2004","unstructured":"Malouf, M. A.  et al. Sexual health issues after lung transplantation: importance of cervical screening. J. Heart Lung Transplant. 23, 894\u2013897 (2004).","journal-title":"J. Heart Lung Transplant."},{"key":"BFnrrheum2009279_CR86","first-page":"359","volume":"45","author":"R Porreco","year":"1975","unstructured":"Porreco, R., Penn, I., Droegemueller, W., Greer, B. & Makowski, E. Gynecologic malignancies in immunosuppressed organ homograft recipients. Obstet. Gynecol. 45, 359\u2013364 (1975).","journal-title":"Obstet. Gynecol."},{"key":"BFnrrheum2009279_CR87","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/j.1572-0241.2007.01582.x","volume":"103","author":"S Kane","year":"2008","unstructured":"Kane, S., Khatibi, B. & Reddy, D. Higher incidence of abnormal Pap. smears in women with inflammatory bowel disease. Am. J. Gastroenterol. 103, 631\u2013636 (2008).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrrheum2009279_CR88","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1136\/pgmj.2003.009332","volume":"80","author":"A Somasekar","year":"2004","unstructured":"Somasekar, A. & Alcolado, R. Genital condylomata in a patient receiving infliximab for Crohn's disease. Postgrad. Med. J. 80, 358\u2013359 (2004).","journal-title":"Postgrad. Med. J."},{"key":"BFnrrheum2009279_CR89","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S0002-9394(02)01499-X","volume":"134","author":"C Cursiefen","year":"2002","unstructured":"Cursiefen, C.  et al. Multiple bilateral eyelid molluscum contagiosum lesions associated with TNFalpha-antibody and methotrexate therapy. Am. J. Ophthalmol. 134, 270\u2013271 (2002).","journal-title":"Am. J. Ophthalmol."},{"key":"BFnrrheum2009279_CR90","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1159\/000117709","volume":"216","author":"C Antoniou","year":"2008","unstructured":"Antoniou, C., Kosmadaki, M. G., Stratigos, A. J. & Katsambas, A. D. Genital HPV lesions and molluscum contagiosum occurring in patients receiving anti-TNF-alpha therapy. Dermatology 216, 364\u2013365 (2008).","journal-title":"Dermatology"},{"key":"BFnrrheum2009279_CR91","first-page":"601","volume":"3","author":"DR Adams","year":"2004","unstructured":"Adams, D. R., Zaenglein, A. L. & Hershey, M. S. Etanercept and warts. J. Drugs Dermatol. 3, 601 (2004).","journal-title":"J. Drugs Dermatol."},{"key":"BFnrrheum2009279_CR92","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1258\/ijsa.2008.008186","volume":"19","author":"I Gur","year":"2008","unstructured":"Gur, I. The epidemiology of Molluscum contagiosum in HIV-seropositive patients: a unique entity or insignificant finding? Int. J. STD AIDS 19, 503\u2013506 (2008).","journal-title":"Int. J. STD AIDS"},{"key":"BFnrrheum2009279_CR93","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.ncl.2008.03.007","volume":"26","author":"T Weber","year":"2008","unstructured":"Weber, T. Progressive multifocal leukoencephalopathy. Neurol. Clin. 26, 833\u2013854 (2008).","journal-title":"Neurol. Clin."},{"key":"BFnrrheum2009279_CR94","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/S0140-6736(71)91777-6","volume":"1","author":"B Padgett","year":"1971","unstructured":"Padgett, B., Walker, D., ZuRhein, G., Eckroade, R. & Dessel, B. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1, 1257\u20131260 (1971).","journal-title":"Lancet"},{"key":"BFnrrheum2009279_CR95","unstructured":"TYSABRI Update. Biogen Idec [online], (2009)."},{"key":"BFnrrheum2009279_CR96","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1056\/NEJMoa051586","volume":"353","author":"GVRM Van Assche","year":"2005","unstructured":"Van Assche, G. V. R. M.  et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 353, 362\u2013368 (2005).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 3","key":"BFnrrheum2009279_CR97","doi-asserted-by":"crossref","first-page":"iii64","DOI":"10.1136\/ard.2008.097972","volume":"67","author":"L Calabrese","year":"2008","unstructured":"Calabrese, L. & Molloy, E. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann. Rheum. Dis. 67 (Suppl. 3), iii64\u2013iii65 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2009279_CR98","first-page":"5","volume":"7","author":"W Sterry","year":"2009","unstructured":"Sterry, W.  et al. Immunosuppressive therapy in dermatology and PML. JDDG 7, 5 (2009).","journal-title":"JDDG"},{"key":"BFnrrheum2009279_CR99","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jaut.2007.11.013","volume":"30","author":"EJ Boren","year":"2008","unstructured":"Boren, E. J., Cheema, G. S., Naguwa, S. M., Ansari, A. A. & Gershwin, M. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J. Autoimmun. 30, 90\u201398 (2008).","journal-title":"J. Autoimmun."},{"key":"BFnrrheum2009279_CR100","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10072-008-0857-x","volume":"29","author":"S Bonavita","year":"2008","unstructured":"Bonavita, S.  et al. Infratentorial progressive multifocal leukoencephalopathy in a patient treated with fludarabine and rituximab. Neurol. Sci. 29, 37\u201339 (2008).","journal-title":"Neurol. Sci."},{"key":"BFnrrheum2009279_CR101","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1136\/gut.2008.163642","volume":"58","author":"H Fidder","year":"2009","unstructured":"Fidder, H.  et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 58, 501\u2013508 (2009).","journal-title":"Gut"},{"key":"BFnrrheum2009279_CR102","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3109\/s10165-006-0530-2","volume":"17","author":"M Yamamoto","year":"2007","unstructured":"Yamamoto, M.  et al. Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis. Mod. Rheumatol. 17, 72\u201374 (2007).","journal-title":"Mod. Rheumatol."},{"key":"BFnrrheum2009279_CR103","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1212\/WNL.52.2.253","volume":"52","author":"I Koralnik","year":"1999","unstructured":"Koralnik, I., Boden, D., Mai, V., Lord, C. & Letvin, N. JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology 52, 253\u2013260 (1999).","journal-title":"Neurology"},{"key":"BFnrrheum2009279_CR104","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1055\/s-2008-1040840","volume":"19","author":"T Weber","year":"1999","unstructured":"Weber, T. Cerebrospinal fluid analysis for the diagnosis of human immunodeficiency virus-related neurologic diseases. Semin. Neurol. 19, 223\u2013233 (1999).","journal-title":"Semin. Neurol."},{"key":"BFnrrheum2009279_CR105","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","volume":"44","author":"N Mohan","year":"2001","unstructured":"Mohan, N.  et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 44, 2862\u20132869 (2001).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009279_CR106","first-page":"1018","volume":"33","author":"J Jarand","year":"2006","unstructured":"Jarand, J., Zochodne, D., Martin, L. & Voll, C. Neurological complications of infliximab. J. Rheumatol. 33, 1018\u20131020 (2006).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2009279_CR107","doi-asserted-by":"publisher","first-page":"174","DOI":"10.7326\/0003-4819-136-2-200201150-00020","volume":"136","author":"D Smith","year":"2002","unstructured":"Smith, D. & Letendre, S. Viral pneumonia as a serious complication of etanercept therapy. Ann. Intern. Med. 136, 174 (2002).","journal-title":"Ann. Intern. Med."},{"key":"BFnrrheum2009279_CR108","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/j.jinf.2006.03.025","volume":"54","author":"NM Ahmad","year":"2007","unstructured":"Ahmad, N. M., Ahmad, K. M. & Younus, F. Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease. J. Infect. 54, e29\u2013e32 (2007).","journal-title":"J. Infect."},{"key":"BFnrrheum2009279_CR109","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3904\/kjim.2007.22.1.63","volume":"22","author":"M-J Kang","year":"2007","unstructured":"Kang, M.-J.  et al. Adenoviral pneumonia during etanercept treatment in a patient with rheumatoid arthritis. Korean J. Intern. Med. 22, 63\u201366 (2007).","journal-title":"Korean J. Intern. Med."},{"key":"BFnrrheum2009279_CR110","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/art.23721","volume":"59","author":"K Saag","year":"2008","unstructured":"Saag, K.  et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 59, 762\u2013784 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2009279_CR111","unstructured":"Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices (ACIP): Use of vaccines and immune globulins in persons with altered immunocompetence. MMWR 42, 1\u201318 (1993)."},{"key":"BFnrrheum2009279_CR112","first-page":"1","volume":"57","author":"R Harpaz","year":"2008","unstructured":"Harpaz, R., Ortega-Sanchez, I. & Seward, J. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices. MMWR 57, 1\u201330 (2008).","journal-title":"MMWR"},{"key":"BFnrrheum2009279_CR113","volume-title":"American College of Rheumatology Hotline","author":"J Cush","year":"2008","unstructured":"Cush, J., Calabrese, L. & Kavanaugh, A. Herpes zoster (shingles) vaccine guidelines for immunosuppressed patients. American College of Rheumatology Hotline http:\/\/www.rheumatology.org\/publications\/hotline\/2008_08_01_shingles.asp (2008)."},{"key":"BFnrrheum2009279_CR114","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(09)60691-7","volume":"373","author":"N Mu\u00f1oz","year":"2009","unstructured":"Mu\u00f1oz, N.  et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24\u201345 years: a randomised, double-blind trial. Lancet 373, 1949\u20131957 (2009).","journal-title":"Lancet"},{"key":"BFnrrheum2009279_CR115","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1056\/NEJMct0806938","volume":"361","author":"J Kahn","year":"2009","unstructured":"Kahn, J. HPV vaccination for the prevention of cervical intraepithelial neoplasia. N. Engl. J. Med. 361, 271\u2013278 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2009279_CR116","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1600-6143.2007.02051.x","volume":"8","author":"R Avery","year":"2007","unstructured":"Avery, R. & Michaels, M. Update on immunizations in solid organ transplant recipients: what clinicians need to know. Am. J. Transplant. 8, 9\u201314 (2007).","journal-title":"Am. J. Transplant."},{"key":"BFnrrheum2009279_CR117","unstructured":"Centers for Disease Control and Prevention. Recommended adult immunization schedule\u2014United States, 2009. MMWR 57, Q1\u2013Q4 (2009)."},{"key":"BFnrrheum2009279_CR118","doi-asserted-by":"crossref","unstructured":"Elkayam, O.  et al. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin. Arthritis Rheum. [doi: 10.1016\/j.semarthrit.2008.12.002].","DOI":"10.1016\/j.semarthrit.2008.12.002"},{"key":"BFnrrheum2009279_CR119","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/BOR.0b013e3282ffdeca","volume":"20","author":"H-P Brezinschek","year":"2008","unstructured":"Brezinschek, H.-P., Hofstaetter, T., Leeb, B. F., Haindl, P. & Graninger, W. B. Immunization of patients with rheumatoid arthritis with antitumor necrosis factor alpha therapy and methotrexate. Curr. Opin. Rheumatol. 20, 295\u2013299 (2008).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrrheum2009279_CR120","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1111\/j.1572-0241.2001.03949.x","volume":"96","author":"K Papadakis","year":"2001","unstructured":"Papadakis, K.  et al. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am. J. Gastroenterol. 96, 2137\u20132142 (2001).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrrheum2009279_CR121","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1097\/00042737-200212000-00018","volume":"14","author":"D Helbling","year":"2002","unstructured":"Helbling, D., Breitbach, T. H. & Krause, M. Disseminated cytomegalovirus infection in Crohn's disease following anti-tumour necrosis factor therapy. Eur. J. Gastroenterol. Hepatol. 14, 1393\u20131395 (2002).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"BFnrrheum2009279_CR122","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S1590-8658(02)80205-5","volume":"34","author":"G Actis","year":"2002","unstructured":"Actis, G., Bruno, M., Pinna-Pintor, M., Rossini, F. & Rizzetto, M. Infliximab for treatment of steroid-refractory ulcerative colitis. Digest. Liver Dis. 34, 631\u2013634 (2002).","journal-title":"Digest. Liver Dis."},{"key":"BFnrrheum2009279_CR123","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1086\/428672","volume":"40","author":"M Mizuta","year":"2005","unstructured":"Mizuta, M. & Schuster, M. Cytomegalovirus hepatitis associated with use of anti-tumor necrosis factor-alpha antibody. Clin. Infect. Dis. 40, 1071\u20131072 (2005).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrrheum2009279_CR124","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1086\/500262","volume":"42","author":"MM Kohara","year":"2006","unstructured":"Kohara, M. M. & Blum, R. N. Cytomegalovirus ileitis and hemophagocytic syndrome associated with use of anti-tumor necrosis factor-alpha antibody. Clin. Infect. Dis. 42, 733\u2013734 (2006).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrrheum2009279_CR125","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jcv.2008.06.002","volume":"43","author":"V D'Ovidio","year":"2008","unstructured":"D'Ovidio, V.  et al. Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFalpha therapy. J. Clin. Virol. 43, 180\u2013183 (2008).","journal-title":"J. Clin. Virol."},{"key":"BFnrrheum2009279_CR126","unstructured":"Centers for Disease Control and Prevention. Vaccines and Immunization. http:\/\/www.cdc.gov\/vaccines\/recs\/schedules\/default.htm (2009)."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2009.279.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2009.279","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2009.279.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T03:48:40Z","timestamp":1744343320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2009.279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,9]]},"references-count":126,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["BFnrrheum2009279"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2009.279","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,9]]},"assertion":[{"value":"9 February 2010","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D. H. Solomon has received grants\/research support from Amgen and Abbott. S. Y. Kim declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}